Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 6
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Breast cancer in a cohort of human immunodeficiency virus (HIV)-infected women from Rio de Janeiro, Brazil: a cases series report and an incidence rate estimate BJID
Andrade,Angela Cristina Vasconcelos de; Luz,Paula Mendes; Veloso,Valdiléa Gonçalves; Cardoso,Sandra Wagner; Moreira,Ronaldo Ismerio; Grinsztejn,Beatriz; Friedman,Ruth Khalili.
Tipo: Info:eu-repo/semantics/report Palavras-chave: HIV; Breast neoplasms; Case reports; Incidence.
Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000400016
Imagem não selecionada

Imprime registro no formato completo
CIAPIN1 gene silencing enhances chemosensitivity in a drug-resistant animal model in vivo BJMBR
Wang,X.M.; Gao,S.J.; Guo,X.F.; Sun,W.J.; Yan,Z.Q.; Wang,W.X.; Xu,Y.Q.; Lu,D..
Overexpression of cytokine-induced apoptosis inhibitor 1 (CIAPIN1) contributes to multidrug resistance (MDR) in breast cancer. This study aimed to evaluate the potential of CIAPIN1 gene silencing by RNA interference (RNAi) as a treatment for drug-resistant breast cancer and to investigate the effect of CIAPIN1 on the drug resistance of breast cancer in vivo. We used lentivirus-vector-based RNAi to knock down CIAPIN1 in nude mice bearing MDR breast cancer tumors and found that lentivirus-vector-mediated silencing of CIAPIN1 could efficiently and significantly inhibit tumor growth when combined with chemotherapy in vivo. Furthermore, Western blot analysis showed that both CIAPIN1 and P-glycoprotein expression were efficiently downregulated, and P53 was...
Tipo: Info:eu-repo/semantics/article Palavras-chave: CIAPIN1 gene; Multidrug resistance; RNA interference; MDR1 gene; Breast neoplasms.
Ano: 2014 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2014000400273
Imagem não selecionada

Imprime registro no formato completo
Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancerpatients BJMBR
Katayama,M.L.H.; Brentani,H.; Abreu,A.P.S.; Barbosa,E.M.; Oliveira,C.T.; Góes,J.C.S.; Brentani,M.M.; Folgueira,M.A.A.K..
In breast cancer patients submitted to neoadjuvant chemotherapy (4 cycles of doxorubicin and cyclophosphamide, AC), expression of groups of three genes (gene trio signatures) could distinguish responsive from non-responsive tumors, as demonstrated by cDNA microarray profiling in a previous study by our group. In the current study, we determined if the expression of the same genes would retain the predictive strength, when analyzed by a more accessible technique (real-time RT-PCR). We evaluated 28 samples already analyzed by cDNA microarray, as a technical validation procedure, and 14 tumors, as an independent biological validation set. All patients received neoadjuvant chemotherapy (4 AC). Among five trio combinations previously identified, defined by nine...
Tipo: Info:eu-repo/semantics/other Palavras-chave: Breast neoplasms; Discriminant analysis; Doxorubicin; Drug resistance; Neoadjuvant therapy; Reverse transcriptase-polymerase chain reaction.
Ano: 2010 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010001200012
Imagem não selecionada

Imprime registro no formato completo
Performance of the Gail and Tyrer-Cuzick breast cancer risk assessment models in women screened in a primary care setting with the FHS-7 questionnaire Genet. Mol. Biol.
Vianna,Fernanda Sales Luiz; Giacomazzi,Juliana; Oliveira Netto,Cristina Brinckmann; Nunes,Luciana Neves; Caleffi,Maira; Ashton-Prolla,Patricia; Camey,Suzi Alves.
Abstract Breast cancer (BC) risk assessment models base their estimations on different aspects of a woman’s personal and familial history. The Gail and Tyrer–Cuzick models are the most commonly used, and BC risks assigned by them vary considerably especially concerning familial history. In this study, our aim was to compare the Gail and Tyrer-Cuzick models after initial screening for familial history of cancer in primary care using the FHS-7 questionnaire. We compared 846 unrelated women with at least one positive answer to any of the seven FHS-7 questions (positive group) and 892 unrelated women that answered negatively (negative group). Concordance between BC risk estimates was compared by Bland-Altman graphics. Mean BC risk estimates were higher using...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Breast neoplasms; Risk assessments; Family medical history; Hereditary breast and ovarian cancer.
Ano: 2019 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572019000200232
Imagem não selecionada

Imprime registro no formato completo
RNAi-mediated knockdown of FANCF suppresses cell proliferation, migration, invasion, and drug resistance potential of breast cancer cells BJMBR
Zhao,L.; Li,N.; Yu,J.K.; Tang,H.T.; Li,Y.L.; He,M.; Yu,Z.J.; Bai,X.F.; Zheng,Z.H.; Wang,E.H.; Wei,M.J..
Fanconi anemia complementation group F protein (FANCF) is a key factor, which maintains the function of FA/BRCA, a DNA damage response pathway. However, the functional role of FANCF in breast cancer has not been elucidated. We performed a specific FANCF-shRNA knockdown of endogenous FANCF in vitro. Cell viability was measured with a CCK-8 assay. DNA damage was assessed with an alkaline comet assay. Apoptosis, cell cycle, and drug accumulation were measured by flow cytometry. The expression levels of protein were determined by Western blot using specific antibodies. Based on these results, we used cell migration and invasion assays to demonstrate a crucial role for FANCF in those processes. FANCF shRNA effectively inhibited expression of FANCF. We found...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Fanconi anemia complementation group F protein; Breast neoplasms; Tumor cell line.
Ano: 2014 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2014000100024
Imagem não selecionada

Imprime registro no formato completo
Sentinel node biopsy in breast cancer: results in a large series BJMBR
Carvalho,S.M.T.; Mourão Netto,M.; Lima,E.N.P.; Pimentel,A.M.; Makdissi,F.B.; Osório,C.A.B.T.; Maciel,M.S.; Iyeyasu,H.; Collins,J.B.; Fontes,C.M.; Perina,A.L.; Soares,F.A..
Sentinel lymph node biopsy (SLNB) is an appropriate method for the evaluation of axillary status in cases of early breast cancer. We report our experience in treating cases evaluated using SLNB. We analyzed a total of 1192 cases assessed by means of SLNB from July 1999 to December 2007. SLNB processing was successfully completed in 1154 cases with the use of blue dye or radiolabeled 99mTc-Dextran-500, or both. Of these 1154 patients, 857 were N0(i-) (no regional lymph node metastasis, negative immunohistochemistry, IHC), 96 were N0(i+) (no regional lymph node metastasis histologically, positive IHC, no IHC cluster greater than 0.2 mm) and 201 were N1mi (greater than 0.2 mm, none greater than 2.0 mm). Most of the tumors (70%) were invasive ductal carcinomas...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Breast neoplasms; Sentinel lymph node; Sentinel lymph node biopsy; Completion axillary dissection.
Ano: 2010 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600011
Registros recuperados: 6
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional